A Simpler, Safer Option For Treating Kidney Cancer
Many cases of early-stage kidney cancer can be treated with a relatively new, nonsurgical procedure used to destroy tumors, a new study by a team led by Weill Cornell Medicine and NewYork-Presbyterian suggests. The procedure, called percutaneous ablation, involves the insertion of a needle.06/29/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 29, 2018 Category: Urology & Nephrology Source Type: news

Dr. Pal Discusses the Role of PD-L1 in Metastatic RCC
Sumanta Kumar Pal, MD, associate clinical professor, Department of Medical Oncology and Therapeutics Research, co-director, Kidney Cancer Program, City of Hope, discusses the role of PD-L1 in metastatic renal cell carcinoma (RCC). One of the biggest unanswered questions in the frontline setting of metastatic RCC is the role of PD-L1. Pal says that there is more to the PD-L1 story, particularly considering the findings of the CheckMate-214 trial. There was a clear difference in clinical outcomes for patients who were PD-L1– positive versus PD-L1–negative, Pal explains. Whether that is clinically applicable is not esta...
Source: Kidney Cancer Association - June 28, 2018 Category: Urology & Nephrology Source Type: news

Ipsen and MD Anderson Announce Bench-to-Bedside Cancer Drug Development Partnership
Ipsen, a global biopharmaceutical group, and The University of Texas MD Anderson Cancer Center today announced a global licensing and joint development agreement for a pre-clinical oncology drug candidate discovered by researchers in MD Anderson ’s Institute for Applied Cancer Science (IACS).06/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 27, 2018 Category: Urology & Nephrology Source Type: news

Bristol-Myers' BLA for Opdivo Label Expansion Accepted by FDA
Bristol-Myers Squibb Company BMY announced that the FDA accepted its supplemental Biologics License Application (sBLA) for the label expansion of its blockbuster immuno-oncology drug Opdivo for the indication first-line advanced non-small cell lung cancer (NSCLC) in patients with tumor mutational burden (TMB) ≥10 mutations per megabase (mut/Mb). The FDA set an action date of Feb 20, 2019.06/27/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 27, 2018 Category: Urology & Nephrology Source Type: news

More Frequent Use of Partial Nephrectomy May Benefit Kidney Cancer Patients
To evaluate trends in the use of partial nephrectomy in the United States, researchers collected information about more than 48,000 patients with non-metastatic kidney cancer treated between 1998 and 2007.06/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 13, 2018 Category: Urology & Nephrology Source Type: news

Pembrolizumab Showed Overall Response Rate of Nearly 40 Percent as First-Line Therapy
KEYNOTE-427 is a single-arm, open-label, non-randomized, multi-cohort, Phase 2 study evaluating the safety and efficacy of KEYTRUDA as monotherapy in patients with advanced RCC who have not received prior systemic therapy.06/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 13, 2018 Category: Urology & Nephrology Source Type: news

California emergency room use has actually risen after the passage of Obamacare
Emergency department visits, including those that resulted in hospital admissions, grew an average 4 percent every year from 2010 to 2016.06/13/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - June 13, 2018 Category: Urology & Nephrology Source Type: news

2018 Young Investigator Award Winners
The Kidney Cancer Association has announced the winners of its annual Young Investigator Award (YIA). The award provides funding to promising doctors to pursue careers in kidney cancer research.05/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - May 29, 2018 Category: Urology & Nephrology Source Type: news

JAMA: Payments influence oncologist prescribing
Lead study author Aaron Mitchell said they also found prescriptions increased as the amount of money physicians received went up. Payments for research, by contrast, were not associated with statistically significant differences in prescribing.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

First step to kidney cancer may occur in childhood
A single damaged cell may be all it takes to trigger aggressive and terminal kidney cancer almost a lifetime after the first step towards the disease is taken.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

FDA approves combination for advanced renal cell carcinoma
The approvals were based on CheckMate 214 (NCT02231749), a randomized open-label trial. Patients with previously untreated advanced RCC received nivolumab (3 mg/kg) plus ipilimumab (1 mg/kg) every 3 weeks for 4 doses followed by nivolumab monotherapy (3 mg/kg) every 2 weeks, or sunitinib 50 mg daily for 4 weeks followed by 2 weeks off every cycle.04/17/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 17, 2018 Category: Urology & Nephrology Source Type: news

New Y-trap Technology Shows Promise as Cancer Immunotherapy
A new technology has shown promise in treating several types of tumors in mice that do not respond to cancer immunotherapy medications called checkpoint inhibitors.04/06/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 6, 2018 Category: Urology & Nephrology Source Type: news

Combinations: The Future of Renal Cell Carcinoma Treatment?
Renal cell carcinoma (RCC) is the most common form of kidney cancer, with an estimated 65,340 patients expected to be diagnosed in 2018 in the United States alone. Nearly a third of those patients will be diagnosed with the advanced or metastatic disease.04/05/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 5, 2018 Category: Urology & Nephrology Source Type: news

Nivolumab, ipilimumab combination improves advanced renal cell carcinoma survival
Nivolumab plus ipilimumab improved OS and objective response rates compared with sunitinib among patients with intermediate- and poor-risk advanced renal-cell carcinoma, according to findings published in The New England Journal of Medicine.04/04/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - April 4, 2018 Category: Urology & Nephrology Source Type: news

When you have kidney cancer...
There's one important thing to remember, when you've been diagnosed with kidney cancer. What is it?02/21/2018 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - February 21, 2018 Category: Urology & Nephrology Source Type: news